

# AKUMS DRUGS & PHARMACEUTICALS LTD.

CIN: U24239DL2004PLC125888

Regd. Office: 304, 3<sup>rd</sup> Floor, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034

Email id: [cs@akums.net](mailto:cs@akums.net) , Tel:011-69041000 , Fax: 011-27023256 [www.akums.in](http://www.akums.in)

---

## CERTIFIED TRUE COPY OF MINUTES OF THE MEETING OF BOARD OF DIRECTORS OF AKUMS DRUGS & PHARMACEUTICALS LTD. HELD ON 7<sup>TH</sup> FEBRUARY, 2024 AT DELHI

### APPROVAL AND ADOPTION OF THE DRAFT RED HERRING PROSPECTUS IN RELATION TO THE OFFER

“RESOLVED THAT, in furtherance of the resolution passed by the board of directors of the Company (the “Board”) for approval of the initial public offer of equity shares of the company on 26<sup>th</sup> October, 2023 and the resolution passed by the shareholders of the Company in this regard on 26<sup>th</sup> October, 2023 and subject to applicable laws, the draft of the draft red herring prospectus (the “DRHP”), in respect of the initial public offering of equity shares of face value of ₹ 2 (rupees two) each of the Company (the “Equity Shares”) consisting of a fresh issue of Equity Shares of the Company aggregating up to ₹ 680,00,00,000/- (Rupees six hundred & eighty crore) and an offer for sale of such number of equity shares of the Company by the selling shareholders

which aggregates up to 1,85,98,365 (one crore eighty five lakh ninety eight thousand three hundred and sixty five) Equity Shares of the Company, at such price as may be determined in accordance with the book building process under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and as agreed to by the Company in consultation with the book running lead managers to the Offer (“BRLMs”), as provided to, and tabled before the Board containing the requisite information as prescribed under applicable laws and regulations, be and is hereby approved for filing with Securities and Exchange Board of India (“SEBI”), BSE Limited, National Stock Exchange of India Limited (which together with BSE Limited shall collectively be referred to as the “Stock Exchanges”) and such other authorities or persons as may be required.

For Akums Drugs & Pharmaceuticals Ltd.



Company Secretary

**RESOLVED FURTHER THAT** Managing Directors, chief financial officer and company secretary of the Company be and are hereby authorised to make corrections or modifications, if any, and to finalise the DRHP for purposes of filing with SEBI, the Stock Exchanges, registrar of companies and such other authorities or persons as may be required, issue such certificates and confirmations as may be required and do all acts, deeds, matters and things and undertake such other necessary steps to implement the above resolution, including without limitation, to settle any questions, difficulties or doubts that may arise in relation thereto.

**RESOLVED FURTHER THAT** Managing Directors, chief financial officer and company secretary of the Company be and are hereby severally authorized to sign the said Draft Red Herring Prospectus on behalf of the Company and file the same with the SEBI for their observations and with the relevant stock exchanges for obtaining their in-principle approval and for listing purposes and such other authorities or persons as may be required, issue such certificates and confirmations as may be required and undertake such other necessary steps to implement the afore going resolutions.

**RESOLVED FURTHER THAT** company secretary of the Company be and is hereby authorised to certify the true copy of the aforesaid resolutions.”

**CERTIFIED TRUE COPY**  
For **AKUMS DRUGS & PHARMACEUTICALS LTD**  
For Akums Drugs & Pharmaceuticals Ltd.



**Dharamvir Malik**      **Company Secretary**  
**(Company Secretary)**